The proposed licensed indication is for use (in combination with trastuzumab and docetaxel) in adult patients with HER2-positive metastatic or locally recurrent unresectable breast cancer, who have not received previous anti-HER2 therapy or chemotherapy for their metastatic disease.
Rapid Review
| Commenced | Completed | Outcome |
| 14/01/2013 | 31/01/2013 | Pharmacoeconomic Evaluation Recommended |
Pharmacoeconomic Evaluation
| Commenced | Completed | Outcome |
| 02/05/2013 | 28/08/2013 | Reimbursement not recommended |
The NCPE believes that pertuzumab in combination with trastuzumab and docetaxel is not a cost-effective treatment for adults with HER2-positive metastatic or locally recurrent unresectable breast cancer who have not received previous anti-HER2 therapy or chemotherapy.